GlassScriptPhysician profile
Ryan J Austerman
NPI 1841644168
$36,881.22
in general payments reported to CMS, 2019-2025
27 companies · $2,255 in 2025
The $2,255 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $30K · 2024: $4,145 · 2025: $2,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $30K · Food and Beverage: $3,506 · Travel and Lodging: $3,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $30,000.00 |
| Food and Beverage | $3,506.13 |
| Travel and Lodging | $3,375.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20,805.64 | 2023-2025 | Activa PC, Percept PC Brainsense, Sensight |
| Boston Scientific Corporation | $11,048.06 | 2023-2025 | Vercise, General - Dbs, Wavewriter Alpha Prime 16 |
| Alphatec Spine, INC | $3,410.58 | 2024-2025 | Other - Miscellaneous |
| Kuros Biosciences USA, INC | $244.26 | 2025 | Magnetos |
| Orthofix Medical, INC. | $166.35 | 2024 | Osteostrand Plus, Lattus |
| Kls-Martin L.P. | $150.00 | 2024 | |
| Nevro Corp. | $124.71 | 2023 | Senza |
| Baxter Healthcare | $118.79 | 2023 | Floseal |
| Vanda Pharmaceuticals INC. | $108.36 | 2024-2025 | Ponvory |
| Integra Lifesciences Corporation | $100.33 | 2023 | Biodrestore, Biodfactor, Biofix |
| Biocomposites INC | $83.82 | 2024 | |
| Ucb, INC. | $55.71 | 2025 | Fintepla, Rystiggo |
| Emd Serono, INC. | $54.76 | 2025 | |
| Abbvie INC. | $52.37 | 2025 | |
| Jazz Pharmaceuticals INC. | $51.65 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $46.15 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Providence Medical Technology, INC. | $32.43 | 2025 | |
| Bioventus LLC | $30.00 | 2025 | |
| Lilly USA, LLC | $29.46 | 2025 | Kisunla |
| Neuropace, INC. | $27.00 | 2024 | |
| Lundbeck LLC | $25.05 | 2025 | Vyepti |
| Cycle Pharmaceuticals INC | $23.84 | 2025 | Bafiertam, Tascenso Odt |
| Csl Behring | $23.59 | 2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $19.39 | 2025 | Austedo Xr |
| Eisai INC. | $18.25 | 2025 | |
| Tonix Medicines, INC. | $16.36 | 2025 | Zembrace Symtouch |
| Merz Pharmaceuticals, LLC | $14.31 | 2025 | Inbrija, Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Austerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.